UCB Receives Positive CHMP Opinion for Cimzia in Moderate-to-Severe Plaque Psoriasis

UCB announced on 4/27/18 that the European Committee for Medicinal Products for Human Use (CHMP) has recommended approval of a label extension for Cimzia (certolizumab pegol), to include a new indication in adult patients with moderate-to-severe plaque psoriasis. Cimzia is the first Fc-free, PEGylated anti-TNF to receive a positive CHMP opinion for use in moderate-to-severe plaque psoriasis.[3] The European Commission's (EC) endorsement of the CHMP positive opinion for psoriasis is expected in the second quarter of 2018 and would further broaden the clinical value of Cimzia.